Newer insulin analogue therapies can provide clinical benefits in terms of reduced glycaemic variability or hypoglycaemia risk [19], which may facilitate individuals to achieve glycaemic control; however, in developing countries, these analogues may not be readily available due to issues of access or cost. Here, INS is linked to Hypoglycemia.